Neuroendocrine Transdifferentiation in Human Cancer: Molecular Mechanisms and Therapeutic Targets

Overview

Journal MedComm (2020)

Specialty Health Services

Date 2024 Oct 7

PMID 39372390

Authors

Jun Jiang

Donghui Han

Jiawei Wang

Weihong Wen

Rui Zhang

Weijun Qin

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine transdifferentiation (NEtD), also commonly referred to as lineage plasticity, emerges as an acquired resistance mechanism to molecular targeted therapies in multiple cancer types, predominately occurs in metastatic epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors and metastatic castration-resistant prostate cancer treated with androgen receptor targeting therapies. NEtD tumors are the lethal cancer histologic subtype with unfavorable prognosis and limited treatment. A comprehensive understanding of molecular mechanism underlying targeted-induced plasticity could greatly facilitate the development of novel therapies. In the past few years, increasingly elegant studies indicated that NEtD tumors share key the convergent genomic and phenotypic characteristics irrespective of their site of origin, but also embrace distinct change and function of molecular mechanisms. In this review, we provide a comprehensive overview of the current understanding of molecular mechanism in regulating the NEtD, including genetic alterations, DNA methylation, histone modifications, dysregulated noncoding RNA, lineage-specific transcription factors regulation, and other proteomic alterations. We also provide the current management of targeted therapies in clinical and preclinical practice.

References

Hyun K, Jeon J, Park K, Kim J . Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017; 49(4):e324. PMC: 6130214. DOI: 10.1038/emm.2017.11. View

Park D, Cheng J, McGrath J, Lim M, Cushman C, Swanson S . Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis. Nat Cell Biol. 2020; 22(5):603-615. PMC: 7336275. DOI: 10.1038/s41556-020-0503-2. View

Krebs M, Delord J, Evans T, de Jonge M, Kim S, Meurer M . Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study. Lung Cancer. 2023; 180:107216. DOI: 10.1016/j.lungcan.2023.107216. View

Feng M, Matoso A, Epstein G, Fong M, Park Y, Gabrielson A . Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. 2023; 85(6):523-526. DOI: 10.1016/j.eururo.2023.05.023. View

Kim D, Sun D, Storck W, Welker Leng K, Jenkins C, Coleman D . BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clin Cancer Res. 2021; 27(17):4923-4936. PMC: 8416959. DOI: 10.1158/1078-0432.CCR-20-4968. View

Jia D, Augert A, Kim D, Eastwood E, Wu N, Ibrahim A . Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov. 2018; 8(11):1422-1437. PMC: 6294438. DOI: 10.1158/2159-8290.CD-18-0385. View

Nachmias B, Schimmer A . Targeting nuclear import and export in hematological malignancies. Leukemia. 2020; 34(11):2875-2886. PMC: 7584478. DOI: 10.1038/s41375-020-0958-y. View

Shue Y, Drainas A, Li N, Pearsall S, Morgan D, Sinnott-Armstrong N . A conserved YAP/Notch/REST network controls the neuroendocrine cell fate in the lungs. Nat Commun. 2022; 13(1):2690. PMC: 9110333. DOI: 10.1038/s41467-022-30416-2. View

Fernandes R, Toubia J, Townley S, Hanson A, Dredge B, Pillman K . Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. Cell Rep. 2021; 34(1):108585. DOI: 10.1016/j.celrep.2020.108585. View

10.

Qi J, Nakayama K, Cardiff R, Borowsky A, Kaul K, Williams R . Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell. 2010; 18(1):23-38. PMC: 2919332. DOI: 10.1016/j.ccr.2010.05.024. View

11.

Chan J, Quintanal-Villalonga A, Gao V, Xie Y, Allaj V, Chaudhary O . Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021; 39(11):1479-1496.e18. PMC: 8628860. DOI: 10.1016/j.ccell.2021.09.008. View

12.

Singh N, Ramnarine V, Song J, Pandey R, Padi S, Nouri M . The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021; 12(1):7349. PMC: 8692330. DOI: 10.1038/s41467-021-26901-9. View

13.

Chen C, Tran W, Song K, Sugimoto T, Obusan M, Wang L . Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation. Cancer Cell. 2023; 41(12):2066-2082.e9. PMC: 10878415. DOI: 10.1016/j.ccell.2023.10.009. View

14.

Quigley D, Dang H, Zhao S, Lloyd P, Aggarwal R, Alumkal J . Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018; 174(3):758-769.e9. PMC: 6425931. DOI: 10.1016/j.cell.2018.06.039. View

15.

He Y, Ji Z, Gong Y, Fan L, Xu P, Chen X . Numb/Parkin-directed mitochondrial fitness governs cancer cell fate via metabolic regulation of histone lactylation. Cell Rep. 2023; 42(2):112033. DOI: 10.1016/j.celrep.2023.112033. View

16.

Offin M, Chan J, Tenet M, Rizvi H, Shen R, Riely G . Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. J Thorac Oncol. 2019; 14(10):1784-1793. PMC: 6764905. DOI: 10.1016/j.jtho.2019.06.002. View

17.

Lovnicki J, Gan Y, Feng T, Li Y, Xie N, Ho C . LIN28B promotes the development of neuroendocrine prostate cancer. J Clin Invest. 2020; 130(10):5338-5348. PMC: 7524485. DOI: 10.1172/JCI135373. View

18.

Kim B, Zhang S, Huang Y, Ko K, Jung Y, Jang J . CRACD loss induces neuroendocrine cell plasticity of lung adenocarcinoma. Cell Rep. 2024; 43(6):114286. PMC: 11216895. DOI: 10.1016/j.celrep.2024.114286. View

19.

Du C, Lv C, Feng Y, Yu S . Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression. J Exp Clin Cancer Res. 2020; 39(1):223. PMC: 7576758. DOI: 10.1186/s13046-020-01735-3. View

20.

Canadas I, Thummalapalli R, Kim J, Kitajima S, Jenkins R, Christensen C . Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018; 24(8):1143-1150. PMC: 6082722. DOI: 10.1038/s41591-018-0116-5. View